**Core Concept**
BRAF V600E is a specific mutation in the BRAF gene that leads to the substitution of glutamic acid for valine at position 600. This mutation results in the constitutive activation of the BRAF protein, a key component of the MAPK/ERK signaling pathway, leading to uncontrolled cell proliferation.

**Why the Correct Answer is Right**
The BRAF V600E mutation is a common driver mutation in various cancers, including melanoma, thyroid cancer, and colorectal cancer. The mutation leads to the activation of the MAPK/ERK pathway, promoting cell growth and survival. Targeted therapies, such as vemurafenib and dabrafenib, have been developed to inhibit the BRAF V600E kinase activity, providing a treatment option for patients with these cancers.

**Why Each Wrong Option is Incorrect**
* **Option A:** Papillary thyroid carcinoma is associated with BRAF V600E mutations, which account for approximately 40-80% of cases. Therefore, this option is incorrect.
* **Option B:** Colorectal cancer, particularly metastatic colorectal cancer, can harbor BRAF V600E mutations, which are associated with poor prognosis and resistance to chemotherapy. This option is incorrect.
* **Option C:** Melanoma, particularly cutaneous melanoma, is another cancer type commonly associated with BRAF V600E mutations, which can be targeted by specific therapies. This option is incorrect.

**Clinical Pearl / High-Yield Fact**
BRAF V600E mutations are a common driver mutation in various cancers, and targeted therapies have revolutionized the treatment of these cancers. However, resistance to these therapies can develop, highlighting the need for continued research into novel therapeutic strategies.

**Correct Answer:** D.